John L. Kolman, PhD, Joins BioReliance Corporation As Senior Director, Research and Development

Business Wire, April 22, 2008

ROCKVILLE, Md. -- BioReliance Corporation announced today that John Ludwig Kolman, PhD, has been named Senior Director, Research and Development. He reports to Vice President and Chief Scientific Officer (CSO) David Onions, PhD.

BioReliance Corporation is a leading contract services company that provides biologics safety testing, toxicology, viral manufacturing and laboratory animal diagnostic services to the pharmaceutical and biopharmaceutical industries worldwide.

Dr. Kolman was previously with Invitrogen Corporation (NASDAQ: IVGN) as the Principal Scientist on the HLA Single Antigen Initiative and Lung Cancer Biomarker Programs. Before that he conducted research at the Salk Institute, La Jolla, California, focusing on DNA replication initiation. He is co-inventor of a method to detect multiple antigens (patent pending) and widely published.

After earning an undergraduate degree cum laude with majors in Honors Biology and Chemistry from University of Illinois, Dr. Kolman earned a Master's degree and PhD in Molecular Biophysics and Biochemistry from Yale University.

"I am delighted that John has joined BioReliance as Senior Director of R&D," said Dr. Onions. "He has a tremendous record of achievement in research both in the academic setting and in industry. His appointment, plus our investment in new R&D laboratories, signal a new era in this company's history and reflects our commitment to the development innovative products and services for our customers."

"BioReliance has become a highly dynamic organization, entering a high growth phase based on accelerated and strategic R&D," said Dr. Kolman. "I look forward to working with the elite corps of BioReliance scientists who are committed to bringing novel and essential services to the pharmaceutical industry."

About BioReliance

BioReliance Corporation is a leading specialist provider of cost-effective contract services to the pharmaceutical and biopharmaceutical industries, offering more than 1,000 tests or services related to biologics safety testing, in vitro and in vivo toxicology, viral manufacturing, GMP manufacturing, pre-clinical testing and lab animal health diagnostics. Founded in 1947 as Microbiological Associates, BioReliance is headquartered in Rockville, Maryland, and has primary facilities in Rockville, Glasgow, Scotland and Stirling, Scotland, and employs more than 700 people globally. For more information, visit www.bioreliance.com.